

Status: Currently Official on 15-Feb-2025  
Official Date: Official as of 01-Aug-2023  
Document Type: USP Monographs  
DocId: GUID-10B0BC2C-AB7D-42EB-90D9-3BC5D0104EAD\_3\_en-US  
DOI: [https://doi.org/10.31003/USPNF\\_M47950\\_03\\_01](https://doi.org/10.31003/USPNF_M47950_03_01)  
DOI Ref: v0elb

© 2025 USPC  
Do not distribute

# Medroxyprogesterone Acetate Tablets

### DEFINITION

Medroxyprogesterone Acetate Tablets contain NLT 93.0% and NMT 107.0% of the labeled amount of medroxyprogesterone acetate ( $C_{24}H_{34}O_4$ ).

### IDENTIFICATION

• **A. [SPECTROSCOPIC IDENTIFICATION TESTS \(197\)](#), [Infrared Spectroscopy: 197K](#)**

**Sample:** Triturate a number of Tablets, equivalent to about 25 mg of medroxyprogesterone acetate, with 15 mL of chloroform. Filter, evaporate the chloroform on a steam bath, and dry the residue at 105° for 3 h.

**Acceptance criteria:** Meet the requirements

### ASSAY

• **PROCEDURE**

**Mobile phase:** Acetonitrile and water (40:60)

**Standard solution:** 1 mg/mL of [USP Medroxyprogesterone Acetate RS](#) in acetonitrile

**Sample solution:** Finely powder NLT 20 Tablets. Weigh a portion of the powder, equivalent to 25 mg of medroxyprogesterone acetate, into a 50-mL glass centrifuge tube. Transfer 25 mL of acetonitrile into the tube, shake to wet the powder thoroughly, sonicate for NLT 10 min, and centrifuge. Use the clear supernatant.

**Chromatographic system**

(See [Chromatography \(621\)](#), [System Suitability](#).)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4-mm × 30-cm; packing L1

**Flow rate:** 2 mL/min

**Injection volume:** 10 µL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Tailing factor:** NMT 2

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of medroxyprogesterone acetate ( $C_{24}H_{34}O_4$ ) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

$C_S$  = concentration of [USP Medroxyprogesterone Acetate RS](#) in the *Standard solution* (mg/mL)

$C_U$  = nominal concentration of medroxyprogesterone acetate in the *Sample solution* (mg/mL)

**Acceptance criteria:** 93.0%–107.0%

### PERFORMANCE TESTS

• **[DISSOLUTION \(711\)](#)**

**Medium:** 0.5% sodium lauryl sulfate; 900 mL

**Apparatus 2:** 50 rpm

**Time:** 45 min

**Mobile phase:** Acetonitrile and water (60:40)

**Sodium lauryl sulfate stock solution:** Transfer 180.0 g of sodium lauryl sulfate to a 2000-mL volumetric flask. Add 1500 mL of water, and stir until dissolved. [NOTE—Several hours of stirring are required.] Dilute with water to volume.

**Standard stock solution:** 70 mg of [USP Medroxyprogesterone Acetate RS](#) in 140 mL of *Sodium lauryl sulfate stock solution*. Dilute with water to 250 mL. [NOTE—It may be necessary to sonicate the solution to bring the Reference Standard into solution before dilution with water.] Prepare the *Standard stock solution* fresh daily.

**Standard solution:** Transfer a 20-mL aliquot of *Standard stock solution* into a 1-L volumetric flask. Add 40 mL of *Sodium lauryl sulfate stock solution*, and dilute with water to volume. This solution is stable for up to 7 days.

**Sample solution:** Withdraw 15 mL of the solution under test and filter, discarding the first 5 mL of the filtrate.

**Chromatographic system**

(See [Chromatography \(621\)](#), *System Suitability*.)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 4-mm × 8-cm; packing L7

**Flow rate:** 1.5 mL/min

**Injection volume:** 20 µL

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Tailing factor:** NMT 1.2

**Relative standard deviation:** NMT 2.0%

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of medroxyprogesterone acetate (C<sub>24</sub>H<sub>34</sub>O<sub>4</sub>) dissolved using the responses from the *Sample solution* and *Standard solution*.

**Tolerances:** NLT 50% (Q) of the labeled amount of medroxyprogesterone acetate (C<sub>24</sub>H<sub>34</sub>O<sub>4</sub>) is dissolved.

**Change to read:**

- [UNIFORMITY OF DOSAGE UNITS \(905\)](#): ▲Meet the requirements▲ (CN 1-Aug-2023)

**Procedure for content uniformity**

**Diluent:** Alcohol and water (3:1)

**Standard solution:** 15 µg/mL of [USP Medroxyprogesterone Acetate RS](#) in *Diluent*

**Sample solution:** Nominally 15 µg/mL of medroxyprogesterone acetate in *Diluent* prepared as follows. Transfer 1 Tablet to a volumetric flask, dilute with *Diluent* to volume, and shake for 15 min. Filter, and quantitatively dilute a portion of the filtrate as needed.

**Instrumental conditions**

**Mode:** UV-Vis

**Analytical wavelength:** Maximum at about 242 nm

**Cell:** 1 cm

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of medroxyprogesterone acetate (C<sub>24</sub>H<sub>34</sub>O<sub>4</sub>) in the Tablet taken:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times 100$$

$A_U$  = absorbance of the *Sample solution*

$A_S$  = absorbance of the *Standard solution*

$C_S$  = concentration of [USP Medroxyprogesterone Acetate RS](#) in the *Standard solution* (µg/mL)

$C_U$  = nominal concentration of medroxyprogesterone acetate in the *Sample solution* (µg/mL)

▲ (CN 1-Aug-2023)

**ADDITIONAL REQUIREMENTS**

- **PACKAGING AND STORAGE:** Preserve in well-closed containers.

- [USP REFERENCE STANDARDS \(11\)](#)

[USP Medroxyprogesterone Acetate RS](#)

**Auxiliary Information** - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
MEDROXYPROGESTERONE ACETATE TABLETS	<a href="#">Documentary Standards Support</a>	SM52020 Small Molecules 5

Chromatographic Database Information: [Chromatographic Database](#)

**Most Recently Appeared In:**

Pharmacopeial Forum: Volume No. PF 41(3)

**Current DocID:** GUID-10B0BC2C-AB7D-42EB-90D9-3BC5D0104EAD\_3\_en-US

**DOI:** [https://doi.org/10.31003/USPNF\\_M47950\\_03\\_01](https://doi.org/10.31003/USPNF_M47950_03_01)

**DOI ref:** [v0elb](#)

OFFICIAL